S&P 500   5,086.68 (+0.33%)
DOW   38,934.55 (-0.04%)
QQQ   438.37 (+0.71%)
AAPL   180.40 (-0.56%)
MSFT   409.48 (+0.43%)
META   488.27 (+0.88%)
GOOGL   137.11 (+0.54%)
AMZN   175.06 (+1.10%)
TSLA   200.98 (-0.52%)
NVDA   792.59 (+2.06%)
NIO   5.70 (+4.97%)
AMD   190.03 (+7.64%)
BABA   74.23 (-0.48%)
T   17.00 (+0.24%)
F   12.44 (+1.14%)
MU   90.00 (+0.32%)
CGC   3.29 (-2.08%)
GE   156.18 (+0.37%)
DIS   111.32 (+0.47%)
AMC   4.30 (-13.83%)
PFE   26.77 (-1.00%)
PYPL   60.34 (+0.15%)
XOM   104.72 (+0.38%)
S&P 500   5,086.68 (+0.33%)
DOW   38,934.55 (-0.04%)
QQQ   438.37 (+0.71%)
AAPL   180.40 (-0.56%)
MSFT   409.48 (+0.43%)
META   488.27 (+0.88%)
GOOGL   137.11 (+0.54%)
AMZN   175.06 (+1.10%)
TSLA   200.98 (-0.52%)
NVDA   792.59 (+2.06%)
NIO   5.70 (+4.97%)
AMD   190.03 (+7.64%)
BABA   74.23 (-0.48%)
T   17.00 (+0.24%)
F   12.44 (+1.14%)
MU   90.00 (+0.32%)
CGC   3.29 (-2.08%)
GE   156.18 (+0.37%)
DIS   111.32 (+0.47%)
AMC   4.30 (-13.83%)
PFE   26.77 (-1.00%)
PYPL   60.34 (+0.15%)
XOM   104.72 (+0.38%)
S&P 500   5,086.68 (+0.33%)
DOW   38,934.55 (-0.04%)
QQQ   438.37 (+0.71%)
AAPL   180.40 (-0.56%)
MSFT   409.48 (+0.43%)
META   488.27 (+0.88%)
GOOGL   137.11 (+0.54%)
AMZN   175.06 (+1.10%)
TSLA   200.98 (-0.52%)
NVDA   792.59 (+2.06%)
NIO   5.70 (+4.97%)
AMD   190.03 (+7.64%)
BABA   74.23 (-0.48%)
T   17.00 (+0.24%)
F   12.44 (+1.14%)
MU   90.00 (+0.32%)
CGC   3.29 (-2.08%)
GE   156.18 (+0.37%)
DIS   111.32 (+0.47%)
AMC   4.30 (-13.83%)
PFE   26.77 (-1.00%)
PYPL   60.34 (+0.15%)
XOM   104.72 (+0.38%)
S&P 500   5,086.68 (+0.33%)
DOW   38,934.55 (-0.04%)
QQQ   438.37 (+0.71%)
AAPL   180.40 (-0.56%)
MSFT   409.48 (+0.43%)
META   488.27 (+0.88%)
GOOGL   137.11 (+0.54%)
AMZN   175.06 (+1.10%)
TSLA   200.98 (-0.52%)
NVDA   792.59 (+2.06%)
NIO   5.70 (+4.97%)
AMD   190.03 (+7.64%)
BABA   74.23 (-0.48%)
T   17.00 (+0.24%)
F   12.44 (+1.14%)
MU   90.00 (+0.32%)
CGC   3.29 (-2.08%)
GE   156.18 (+0.37%)
DIS   111.32 (+0.47%)
AMC   4.30 (-13.83%)
PFE   26.77 (-1.00%)
PYPL   60.34 (+0.15%)
XOM   104.72 (+0.38%)
NASDAQ:NEO

NeoGenomics (NEO) Stock Price, News & Analysis

$16.07
+0.51 (+3.28%)
(As of 02:09 PM ET)
Today's Range
$15.64
$16.21
50-Day Range
$14.06
$20.73
52-Week Range
$11.03
$21.22
Volume
586,913 shs
Average Volume
1.04 million shs
Market Capitalization
$2.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.22

NeoGenomics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
19.5% Upside
$19.22 Price Target
Short Interest
Bearish
5.84% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.69mentions of NeoGenomics in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$38,702 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.20) to ($0.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.26 out of 5 stars

Medical Sector

601st out of 958 stocks

Testing Laboratories Industry

1st out of 2 stocks


NEO stock logo

About NeoGenomics Stock (NASDAQ:NEO)

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

NEO Stock Price History

NEO Stock News Headlines

The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
NEO Mar 2024 10.000 put
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
NeoGenomics (NASDAQ:NEO) Given "Outperform" Rating at William Blair
NeoGenomics (NASDAQ:NEO) Shares Gap Up Following Analyst Upgrade
Evaluating NeoGenomics: Insights From 4 Financial Analysts
Q4 2023 Neogenomics Inc Earnings Call
NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates
Recap: NeoGenomics Q4 Earnings
NeoGenomics: Q4 Earnings Snapshot
See More Headlines
Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
2/29/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Testing laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:NEO
Employees
2,100
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$19.22
High Stock Price Target
$24.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+23.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$-87,970,000.00
Pretax Margin
-16.41%

Debt

Sales & Book Value

Annual Sales
$591.64 million
Cash Flow
$0.27 per share
Book Value
$7.38 per share

Miscellaneous

Free Float
125,951,000
Market Cap
$1.99 billion
Optionable
Optionable
Beta
1.12

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Christopher Michael Smith BSc (Age 61)
    CEO & Director
    Comp: $3.52M
  • Mr. Jeffrey S. Sherman M.B.A. (Age 58)
    Chief Financial Officer
    Comp: $492.31k
  • Mr. Vishal Sikri (Age 47)
    President of Advanced Diagnostics Division
    Comp: $1.21M
  • Mr. Warren Stone (Age 51)
    President of Clinical Division
    Comp: $722.79k
  • Ms. Cynthia J. Dieter (Age 49)
    Chief Accounting Officer
  • Mr. Greg Sparks
    Chief Technology Officer
  • Ms. Kendra Sweeney
    Vice President of Investor Relations & Communications
  • Ms. Alicia Olivo (Age 40)
    General Counsel & Corporate Secretary
  • Mr. Hutan Hashemi J.D. (Age 45)
    Chief Compliance Officer
  • Dr. Derek Lyle M.D.
    Chief Medical Officer














NEO Stock Analysis - Frequently Asked Questions

Should I buy or sell NeoGenomics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NEO shares.
View NEO analyst ratings
or view top-rated stocks.

What is NeoGenomics' stock price target for 2024?

11 Wall Street analysts have issued 12-month price targets for NeoGenomics' shares. Their NEO share price targets range from $17.00 to $24.00. On average, they expect the company's share price to reach $19.22 in the next year. This suggests a possible upside of 19.5% from the stock's current price.
View analysts price targets for NEO
or view top-rated stocks among Wall Street analysts.

How have NEO shares performed in 2024?

NeoGenomics' stock was trading at $16.18 at the beginning of 2024. Since then, NEO stock has decreased by 0.6% and is now trading at $16.09.
View the best growth stocks for 2024 here
.

When is NeoGenomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our NEO earnings forecast
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) announced its quarterly earnings data on Thursday, November, 4th. The medical research company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. The medical research company had revenue of $121.30 million for the quarter, compared to analysts' expectations of $125.09 million. NeoGenomics had a negative net margin of 14.87% and a negative trailing twelve-month return on equity of 4.13%. The business's quarterly revenue was down 3.3% on a year-over-year basis. During the same period last year, the company posted $0.04 EPS.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its first quarter 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $148.0 million-$151.0 million, compared to the consensus revenue estimate of $149.4 million.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.12%), Brown Advisory Inc. (7.57%), First Light Asset Management LLC (3.08%), Dimensional Fund Advisors LP (2.36%), Schroder Investment Management Group (1.95%) and Northern Trust Corp (1.25%). Insiders that own company stock include Alicia C Olivo, Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Kathryn B Mckenzie, Mark Mallon, Robert J Shovlin and William Bonello.
View institutional ownership trends
.

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does NeoGenomics have any subsidiaries?
The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC.
Read More
This page (NASDAQ:NEO) was last updated on 2/29/2024 by MarketBeat.com Staff